CogState (CGS.AX) Aktsia Kursus
CogState Kursus
Viimase 19 aasta jooksul kasvas CogState käive 20,0 % aastas ja jõudis 53,09 M USD-ni. Kasum aktsia kohta kasvas 8,5 % aastas viimase 16 aasta jooksul. CogState netomarginaal 19,1 % on tõusnud võrreldes 16,0 %-ga mõni aasta tagasi. Tänase hinna juures on dividenditootlus umbes 1,04 %. Väljamaksesuhe on umbes 34 % kasumist. CogState 12 kuu konsensuse hinnasiht on 2,15 USD, umbes alla kurssi 21,7 %. 6 analüütikust 5 soovitab osta — üldine konsensus on Osta.
CogState aktsiahinnad
CogState ärimudel ja aktsia analüüs
Korduma kippuvad küsimused CogState aktsia kohta
CogState Ltd is a leading provider of cognitive testing services for clinical trials, academic research, and healthcare. The company's business model revolves around using their digital tools and technologies to measure and enhance cognitive function in patients. By collaborating with pharmaceutical companies, academic institutions, and healthcare organizations, CogState Ltd aims to improve patient outcomes and accelerate the development of new treatments. With their expertise and extensive database, CogState Ltd offers customized solutions and prognostic insights to address the cognitive challenges faced in various industries.
CogState Ltd is primarily active in the healthcare and pharmaceutical industries.
The main competitors of CogState Ltd in the market are Cambridge Cognition Holdings PLC, Neurotrack Technologies Inc., and CogniFit Ltd. These companies also specialize in cognitive assessment and provide similar solutions and services. However, CogState Ltd distinguishes itself through its innovative technologies and partnerships, including collaborations with leading pharmaceutical companies. With its strong focus on enhancing the understanding and measurement of cognitive function, CogState Ltd continues to remain competitive in the market and deliver valuable solutions to its clients.
CogState Ltd is a renowned company with a rich history and background. Founded in 1999, CogState specializes in cognitive testing and offers innovative solutions to improve brain health assessment. With its headquarters in Melbourne, Australia, the company has expanded its global presence, serving various sectors including pharmaceuticals, biotechnology, and academic research. CogState has developed cutting-edge technologies and software platforms to deliver accurate and efficient cognitive assessments, benefiting patients, researchers, and professionals worldwide. Known for its advanced cognitive testing methods and commitment to enhancing brain health, CogState Ltd has established itself as a trusted industry leader.
CogState Ltd has achieved several significant milestones in its history. One key achievement is the development and commercialization of its pioneering cognitive testing technology, known as the CogState Computerized Cognitive Assessment Tool (CCAT). This innovative tool is widely utilized in clinical trials and research studies worldwide, enabling precise and objective measurement of cognitive function. Additionally, CogState Ltd has successfully established strategic partnerships with leading pharmaceutical companies, academic institutions, and healthcare providers, facilitating the widespread adoption of its solutions. The company continues to thrive through ongoing research and development, further cementing its position as a global leader in cognitive assessment technology.
CogState Ltd is primarily present in Australia, the United States, and Europe.
CogState Ltd represents a set of core values and a corporate philosophy that drive its operations. The company is committed to innovation, delivering cutting-edge solutions in the fields of cognitive assessment and clinical trials. CogState prioritizes integrity, ensuring transparent and ethical practices in all aspects of its business. With a focus on collaboration, CogState fosters strong partnerships to drive mutual success. The company values dedication to excellence, constantly striving for improvement and delivering high-quality products and services. CogState fosters a customer-centric approach, prioritizing customer satisfaction and delivering tailored solutions. Overall, CogState Ltd embodies a commitment to innovation, integrity, collaboration, excellence, and customer-centricity in its corporate philosophy.
Analüütikud määravad CogState aktsiale keskmiseks hinnasihi 2,15 USD (mediaan: 2,15 USD), mis on −21,7 % viimase hinna suhtes. Konsensus põhineb 6 analüütiku hinnangul.
7 analüütikut hindavad praegu CogState aktsiat: 6 soovitab osta, 1 hoida ja 0 müüa. 2026. aastaks ootavad analüütikud, et CogState teenib tulu 128,65 M USD ja kasumit aktsia kohta 0,09 USD.
Praeguse kursiga kaubeldakse CogState aktsiaga 2,45 EUR (2,75 USD) juures.
CogState aktsia (CGS.AX) on noteeritud 2 börsil, sh: ASX (CGS.AX).
CogState Ltd is an innovative company specializing in the development and marketing of cognitive testing solutions. The company offers a wide range of products and services that can be used in the fields of pharmaceutical research, clinical diagnostics, and sports performance optimization. The three main business divisions of CogState Ltd include research and development of cognitive tests, clinical diagnostics and monitoring of patients with neurodegenerative disorders, and solutions for improving sports performance. The company's products are rooted in today's technology, as they are exclusively offered online. They allow for remote diagnosis and supervision of patients, saving time for therapists and improving diagnostic accuracy. The company's proprietary software platform enables researchers to effectively manage their studies and present study results in a concise format. CogState Ltd has a strategy in place to continue offering unique and expanding product offerings, allowing the company to remain a strong competitor in the industry.
oodatav CogState käive on 128,65 M USD. See näitaja põhineb praegusel finantsandmetel ja peegeldab ettevõtte äritulemuseid.
oodatav CogState kasum on 16,22 M USD. Netokasum peegeldab ettevõtte kasumlikkust pärast kõigi kulude mahaarvamist.
Võrdlusarvud hinna ja kasumiga (P/E) CogState jaoks on praegu 29,48. P/E-suhtarv võrdleb praegust aktsiahinnad kasumiga aktsia kohta ja aitab investoritel hinnata CogState aktsia väärtust.
Kursuse ja müügimahu suhe (P/S) CogState jaoks on praegu 3,72. P/S-suhtarv võrdleb börsikapitalisatsooni aastase tuluga ja teenib hindamismõõdikuna CogState aktsia jaoks.
Eulpooli kvaliteedinäitaja CogState jaoks on 6/10.
CogState ISIN on AU000000CGS8. ISIN (rahvusvaheline väärtpaberi identifitseerimise number) on väärtpaberite globaalne unikaalne tuvastaja.
CogState ticker on CGS.AX. Ticker-sümbol kasutatakse CogState aktsiate kauplemiseks börsil.
CogState aktsia
CogState konkurendid
CogState Börsiticker
CogState FIGI
Kõik teised näitajad ja analüüsid CogState kohta sügavamalt
Meie CogState-aktsia analüüs sisaldab olulisi finantsnäitajaid, nagu käive, kasum, P/E suhe, P/S suhe, EBIT, samuti teavet dividendi kohta. Lisaks käsitleme aspekte nagu aktsiad, turukapitalisatsioon, võlad, omakapital ja kohustused ettevõttes CogState. Kui otsite nende teemade kohta põhjalikumat teavet, pakume teile meie alamlehtedel üksikasjalikke analüüse: